Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy Corrigendum in /10.3892/mco.2021.2317

Teishima,Jun; Murata,Daiki; Inoue,Shogo; Hayashi,Tetsutaro; Mita,Koji; Hasegawa,Yasuhisa; Kato,Masao; Kajiwara,Mitsuru; Shigeta,Masanobu; Maruyama,Satoshi; Moriyama,Hiroyuki; Fujiwara,Seiji

doi:10.3892/mco.2020.2020

Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy

Corrigendum in: /10.3892/mco.2021.2317

Authors:
- Jun Teishima
- Daiki Murata
- Shogo Inoue
- Tetsutaro Hayashi
- Koji Mita
- Yasuhisa Hasegawa
- Masao Kato
- Mitsuru Kajiwara
- Masanobu Shigeta
- Satoshi Maruyama
- Hiroyuki Moriyama
- Seiji Fujiwara
View Affiliations

Affiliations: Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan, Department of Urology, Hiroshima‑City Asa Citizens Hospital, Hiroshima 731‑0293, Japan, Department of Urology, Fukuyama Medical Center, Fukuyama, Hiroshima 720‑8520, Japan, Department of Urology, Hiroshima General Hospital, Hatsukaichi, Hiroshima 738‑8503, Japan, Department of Urology, Hiroshima Prefectural Hospital, Hiroshima 734‑8530, Japan, Department of Urology, Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima 737‑0023, Japan, Department of Urology, Miyoshi Central Hospital, Miyoshi, Tokushima 728‑8502, Japan, Department of Urology, Onomichi General Hospital, Onomichi, Hiroshima 722‑8508, Japan, Department of Urology, Higashi‑Hiroshima Medical Center, Higashi‑Hiroshima, Hiroshima 739‑0041, Japan
Published online on: March 24, 2020 https://doi.org/10.3892/mco.2020.2020
Pages: 557-564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the outcomes of targeted therapy for elderly patients with metastatic renal cell carcinoma (mRCC). A total of 277 patients with mRCC who were treated with tyrosine kinase inhibitor as a first‑line therapy from January 2008 to May 2018 were retrospectively investigated by reviewing clinicopathological data. Patients 75 years or older were classified into the older‑aged group (n=55) while all others were classified into the younger‑aged group (n=222). The preoperative clinicopathological characteristics and the overall survival (OS) rate for these two groups were subsequently compared. The median age in the older‑ and younger‑aged groups was 78 and 63 years (P<0.0001), respectively. A total of 7, 42 and 6 cases in the older‑aged group and 46, 118 and 58 cases in the younger‑aged group were classified into favorable, intermediate, and poor risk groups, respectively. The rate of patients with cardiovascular diseases (29.1%) and malignant diseases other than RCC (20.0%) was significantly higher in the older‑aged group compared with the younger‑aged group (6.8%; P<0.0001 and 7.2%; P=0.0042, respectively). There was a significant improvement in the OS rate for patients beginning targeted therapy after 2011 compared with those starting therapy prior to 2010. The 50% OS rate in patients starting targeted therapy before 2010 and after 2011 was, respectively, 17.1 and 38.6 months for the older‑aged group (P=0.0066), while there was no significant difference for the younger‑aged group (P=0.1441; 50% OS; 35.9 vs. 30.5 months). The results of the present study indicated that the prognosis for older patients has improved since the introduction of targeted therapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
2	Pal SK, Nelson RA and Vogelzang N: Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One. 8(e63341)2013.PubMed/NCBI View Article : Google Scholar
3	Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N and Vogelzang NJ: Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: A SEER-medicare database analysis. Clin Genitourin Cancer. 15:e573–e582. 2017.PubMed/NCBI View Article : Google Scholar
4	Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH, Brenner H and Coebergh JW: Clinical relevance of conditional survival of cancer patients in Europe: Age-specific analyses of 13 cancers. J Clin Oncol. 28:2520–2528. 2010.PubMed/NCBI View Article : Google Scholar
5	Pal SK, Vanderwalde A, Hurria A and Figlin RA: Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging. 28:635–649. 2011.PubMed/NCBI View Article : Google Scholar
6	Miyake H, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T and Otsuka A: Significance of age in Japanese patients receiving sunitinib as first-line systemic therapy for metastatic renal cell carcinoma: Comparative assessment of efficacy and safety between patients aged <75 and ≥75 years. Anticancer Res. 38:3593–3599. 2018.PubMed/NCBI View Article : Google Scholar
7	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
8	Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 369:722–731. 2013.PubMed/NCBI View Article : Google Scholar
9	Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.PubMed/NCBI View Article : Google Scholar
10	Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
11	Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 14:552–562. 2013.PubMed/NCBI View Article : Google Scholar
12	Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, et al: European Association of urology guidelines on renal cell carcinoma: The 2019 Update. Eur Urol. 75:799–810. 2019.PubMed/NCBI View Article : Google Scholar
13	NCCN clinical practice guidelines in oncology (NCCN guidelines) Kidney Cancer. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
14	Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, et al: Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 32:1412–1418. 2014.PubMed/NCBI View Article : Google Scholar
15	De Giorgi U, Scarpi E, Sacco C, Aieta M, Lo Re G, Sava T, Masini C, De Vincenzo F, Baldazzi V, Camerini A, et al: Standard vs. adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: Results from a large retrospective analysis. Clin Genitourin Cancer. 12:182–189. 2014.PubMed/NCBI View Article : Google Scholar
16	Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, et al: Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 110:1125–1132. 2014.PubMed/NCBI View Article : Google Scholar
17	Brunello A, Basso U, Sacco C, Sava T, De Vivo R, Camerini A, Barile C, Roma A, Maruzzo M, Falci C, et al: Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: A multicenter study. Ann Oncol. 24:336–342. 2013.PubMed/NCBI View Article : Google Scholar
18	Poprach A, Lakomy R, Bortlicek Z, Melichar B, Pavlik T, Slaby O, Vyzula R, Svoboda M, Kiss I, Studentova H, et al: Efficacy of sunitinib in elderly patients with metastatic renal cell carcinoma: Data from real-world clinical practice. Drugs Aging. 33:655–663. 2016.PubMed/NCBI View Article : Google Scholar
19	Dutcher JP, Tannir N, Bellmunt J and Escudier B: Experience with sorafenib and the elderly patient. Med Oncol. 27:1359–1370. 2010.PubMed/NCBI View Article : Google Scholar
20	Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM and Jonasch E: Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 191:611–618. 2014.PubMed/NCBI View Article : Google Scholar
21	Khambati HK, Choueiri TK, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan MH, MacKenzie MJ, et al: Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. Clin Genitourin Cancer. 12:354–358. 2014.PubMed/NCBI View Article : Google Scholar
22	Teishima J, Inoue S, Hayashi T and Matsubara A: Current status of prognostic factors in patients with metastatic renal cell carcinoma. Int J Urol. 26:608–617. 2019.PubMed/NCBI View Article : Google Scholar
23	De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, et al: Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 25:3839–3846. 2019.PubMed/NCBI View Article : Google Scholar